Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Regulatory News (TYR)

  • There is currently no data for TYR

Board Changes

16 Sep 2009 07:01

RNS Number : 1250Z
TyraTech, Inc.
16 September 2009
Β 

ο»Ώ

For immediate release

16 SeptemberΒ 2009

TYRATECH, INC.

("TyraTech" or "the Company")

Board Changes

TyraTech, Inc. (AIM: TYR), aΒ leading independent novel eco-technology company for human, animal and environmental health, is pleased to announce thatΒ Patrick ReganΒ will join the BoardΒ as aΒ Non-Executive Director andΒ thatΒ DavidΒ PaulΒ SzostakΒ will step down from the Board asΒ aΒ Non-ExecutiveΒ Director.Β MrΒ Szostak joined the Board in April 2008Β to represent XL TechGroupΒ andΒ willΒ nowΒ step down from the Board.Β Both changes take placeΒ with immediate effect.Β 

Mr ReganΒ thirty sevenΒ joins the Board as a representative of theΒ Laurus-ValensΒ Group, the parent Group ofΒ PetroTech Holdings Corporation,Β which has a 45.69% shareholding in TyraTech.Β HeΒ bringsΒ to the Board overΒ sixteenΒ years of financial analysis,Β corporateΒ management,Β investment banking and venture capitalΒ experience gained in theΒ US.Β Mr ReganΒ hasΒ beenΒ a senior managing director for Laurus Capital Management LLC since 2001 andΒ hasΒ also servedΒ the same role at Valens Capital Management LLC since its establishment in 2007.Β 

In addition to hisΒ fund management experience atΒ Laurus-Valens, heΒ hasΒ spent four years as a financial analyst at Geller & Company, a financial services accounting firm,Β primarily providing CFO functions to private companies and financial planning for high net worth individuals. At Geller,Β he was involved in private placement financing, management consulting and general corporate finance functions.Β Between 1999 and 2001,Β PatrickΒ Regan was an associate at Tower Hill Capital Group, an investment banking boutique and venture capital firm.

Mr Regan has a Bachelor of Science in Business and Economics fromΒ LehighΒ UniversityΒ and an MBA fromΒ FordhamΒ University.Β 

Mr. ReganΒ has no otherΒ previousΒ orΒ current Directorships.Β 

There are no further details required to be disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules.

Commenting on the board changesΒ Geoffrey Vernon, Chairman of TyraTech,Β said:

"I am delighted to welcomeΒ Patrick ReganΒ to the Board as he brings a wealth of experience of matters across a range of different areas important toΒ TyraTech.Β His understanding of the financial dynamics of small cap companiesΒ and hisΒ investment banking and venture capitalΒ experienceΒ will be beneficial to the Group."

"I would like to express my sincere gratitude to DavidΒ for his experience and expertise throughout his timeΒ at TyraTechΒ and wish him well for the future. His contribution has beenΒ highlyΒ valuable."

For further information please contact:

For further information please contact:

TyraTech Inc.

Douglas Armstrong Ph.D., Chief Executive Officer +1 (321) 409 7723

Keith Bigsby, Chief Financial Officer +1 (321) 409 7714

www.tyratech.com

Nomura Code Securities

Charles Walker/Clare Terlouw +44 (0)20 7776 1200

www.nomuracode.com

Buchanan Communications

Mary-Janeί›Β ElliottΒ / Lisa Baderoon +44 (0)20 7466 5000 / Catherine Breen / Stasa Filiplic

www.buchanan.uk.com

About TyraTech

TyraTech was formed in 2004 to develop and commercialise products for the control of invertebrate pests and pathogens using the Company's proprietary technology. TyraTech,Β which already has productsΒ on the market, is positioned for human health, animal health and pesticide market opportunities which total over $32 billion globally. TyraTech'sΒ Nature's Technology provides the Company with a wide variety of product and business opportunities in many markets and geographic regions. The differentiating feature of these products is the potential to have a combined level of potency and safety that other invertebrate control products are unable to offer. TyraTech's platform brings many of the principles of drug discovery and development to the fields of insecticides and parasiticides. By targeting specific chemoreceptors that are found in invertebrates but not in humans and animals, TyraTech can produce products that use natural plant derived compounds targeting these receptors.

TyraTech's plan for the use of its technology is to develop selected proprietary active ingredients which can then be used across a wide variety of market segments, either by development partners or by TyraTech itself. TyraTech already has products or partnerships in the areas of professional and horticultural insect control, andΒ for consumer and professional pest control. TyraTech also has an innovative partnership with Kraft to use its natural oils to develop functional foods for improving the health of the more than 2 billion people worldwide subject to intestinal parasitic infections.

TyraTech also has a separate technology with associated intellectual property that is the basis for the Sustainable Solutions business. This technology has been incorporated into specialised dairy farm equipment for processing cattle manure waste to a usable material for TyraTech to sell as a commercial plant growing medium. For more information please visitΒ www.tyratech.comΒ 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BOAMGGMLMKGGLZZ
Date   Source Headline
14th Jan 20147:00 amRNSChange of Adviser
14th Jan 20147:00 amRNSVamousse coming to Walmart stores in the USA
18th Dec 20137:00 amRNSBlocklisting Interim Review
25th Oct 20132:39 pmRNSDirector/PDMR Shareholding
7th Oct 20138:39 amRNSDirector/PDMR Shareholding
30th Sep 20137:00 amRNSInterim Results
14th Aug 20137:00 amRNSGlobal distribution agreement for biocide products
25th Jul 20136:11 pmRNSResult of AGM
27th Jun 20137:00 amRNSFinal Results
24th Jun 20137:00 amRNSDirectorate Changes
19th Jun 20139:59 amRNSBlocklisting Interim Review
11th Jun 20134:23 pmRNSDirectorate Change
31st May 201312:43 pmRNSMigration of Shares
11th Apr 20137:00 amRNSFrench Registration of Insect Repellent Product
9th Apr 20137:00 amRNSHolding(s) in Company
28th Mar 20136:09 pmRNSResult of Special Meeting
28th Mar 20134:15 pmRNSShare Migration
19th Mar 20137:00 amRNSAppointment of Financial PR and IR advisor
18th Mar 20137:00 amRNSProposed placing and subscription of common shares
4th Mar 20137:00 amRNSUK registration of insect repellent product
4th Feb 20137:00 amRNSFirst Patent Granted for ExtendT Technology
30th Jan 20137:00 amRNSAMVAC and TyraTech Name New Joint Venture
10th Jan 20137:00 amRNSDirectorate Change
7th Jan 201310:40 amRNSNew Anti-Endoparasitic Composition Patents
20th Dec 20127:00 amRNSIssue of Equity
18th Dec 20122:56 pmRNSBlocklisting Interim Review
18th Dec 20127:00 amRNSGerman Registration of Insect Repellent Product
17th Dec 20127:00 amRNSFirst Shipment of Retail Products
11th Dec 20127:00 amRNSHead Lice Product Registration in UK
4th Dec 20127:00 amRNSFormation of New Joint Venture
13th Nov 20127:00 amRNSU.S. Registration of New Insect Repellent Product
7th Nov 20122:10 pmRNSProactive Investors One2One Investor Forum
30th Oct 20127:00 amRNSAdvance Payment on Prospective New Alliance
29th Oct 20127:00 amRNSChange of Name of Adviser
16th Oct 201211:40 amRNSTyraTech Secures New Patent
16th Oct 20129:26 amRNSMigration of Shares
1st Oct 20127:00 amRNSInterim Results
28th Sep 20121:15 pmRNSInterim Results
26th Sep 20127:00 amRNSProducts to Launch at The Home Depot
25th Sep 20127:00 amRNSTrademark Licensing Agreement with Terminix
10th Aug 20123:02 pmRNSMigration of Shares
25th Jul 20123:55 pmRNSResult of AGM
6th Jul 20124:36 pmRNSMigration of Shares
2nd Jul 20121:18 pmRNSDirector/PDMR Shareholding
2nd Jul 201211:39 amRNSDirector/PDMR Shareholding
28th Jun 20127:00 amRNSFinal Results
18th Jun 20127:00 amRNSBlocklisting Interim Review
22nd May 20127:00 amRNSTrading Update
14th May 20127:00 amRNSIssue of Equity
10th May 20127:00 amRNSMigration of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.